Zydus Lifesciences Sees Sharp Open Interest Surge Amid Bullish Momentum

Open Interest and Volume Dynamics

The open interest (OI) in Zydus Lifesciences’ futures and options contracts jumped from 16,676 to 20,470 contracts, an increase of 3,794 contracts or 22.75% on 23 April 2026. This surge in OI was accompanied by a robust volume of 28,038 contracts traded, reflecting active participation from derivatives traders. The futures segment alone accounted for a value of approximately ₹66,766.56 lakhs, while the options segment’s notional value stood at an impressive ₹17,628.71 crores, culminating in a total derivatives market value of ₹68,596.19 lakhs for the stock.

This spike in open interest, coupled with elevated volumes, suggests that market participants are either initiating new positions or adding to existing ones, rather than merely closing out trades. Such a pattern often precedes significant price movements, as it reflects increased conviction among traders regarding the stock’s near-term direction.

Price Performance and Technical Context

Zydus Lifesciences has outperformed its Pharmaceuticals & Biotechnology sector, which gained 2.12% on the day, by registering a 2.54% increase. The stock touched an intraday high of ₹962.90, marking a 3.55% rise from its previous close. Notably, the stock is trading above all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – signalling a strong bullish technical setup.

Despite this positive momentum, delivery volumes have declined sharply by 37.86% compared to the five-day average, with only 1.45 lakh shares delivered on 22 April. This drop in investor participation at the delivery level may indicate that the recent gains are being driven more by speculative activity in the derivatives market rather than sustained buying from long-term investors.

Market Positioning and Directional Bets

The sharp rise in open interest alongside strong volume suggests that traders are positioning for a potential upward move in Zydus Lifesciences. The stock’s underlying value currently stands at ₹952, and the recent price action pushing it above ₹960 indicates bullish sentiment. The increase in futures value to ₹66,766.56 lakhs further supports the view that institutional and proprietary traders are actively building long positions.

However, the MarketsMOJO Mojo Score for Zydus Lifesciences remains at 48.0, with a Mojo Grade downgraded from Hold to Sell as of 1 December 2025. This rating reflects caution due to valuation concerns or sector headwinds despite the recent positive price momentum. The company is classified as a mid-cap with a market capitalisation of ₹94,702 crores, placing it in a segment where volatility can be more pronounced.

Investors should note that while derivatives activity often foreshadows price trends, it can also amplify short-term volatility. The falling delivery volumes imply that the rally may be driven more by speculative flows than by fundamental buying, which could lead to sharp corrections if market sentiment shifts.

Sector and Benchmark Comparison

In comparison to the broader Pharmaceuticals & Biotechnology sector, which gained 2.12% on the day, Zydus Lifesciences outperformed by 0.3 percentage points. Meanwhile, the Sensex declined by 0.68%, highlighting the stock’s relative strength amid a broadly negative market environment. This divergence underscores the stock’s appeal as a defensive or sector-specific play in the current market context.

Liquidity remains adequate for sizeable trades, with the stock’s average traded value supporting a trade size of approximately ₹0.83 crore based on 2% of the five-day average traded value. This liquidity profile is favourable for institutional investors seeking to enter or exit positions without significant market impact.

Implications for Investors

The recent surge in open interest and volume in Zydus Lifesciences’ derivatives market signals increased speculative interest and potential directional bets on the stock’s upside. While the technical indicators and price action support a bullish stance, the downgrade in Mojo Grade to Sell and declining delivery volumes counsel caution.

Investors should closely monitor the evolution of open interest and price trends in the coming sessions to gauge whether the derivatives activity translates into sustained buying or if it represents short-term positioning that could unwind quickly. Given the mid-cap status and sector volatility, risk management remains paramount.

Overall, Zydus Lifesciences presents a mixed picture: strong technical momentum and derivatives interest contrast with cautious fundamental ratings and reduced investor participation at the delivery level. This dynamic warrants a balanced approach, favouring nimble trading strategies over long-term commitments until clearer signals emerge.

Conclusion

Zydus Lifesciences Ltd’s derivatives market has experienced a notable increase in open interest and volume, reflecting heightened market activity and potential bullish bets. The stock’s outperformance relative to its sector and the Sensex, combined with its position above key moving averages, supports a positive near-term outlook. However, the downgrade in Mojo Grade and falling delivery volumes suggest that investors should remain vigilant and consider the risks of speculative-driven volatility.

As the pharmaceutical sector continues to navigate regulatory and market challenges, Zydus Lifesciences’ evolving derivatives positioning will be a key indicator for traders and investors alike. Monitoring these metrics alongside fundamental developments will be essential for informed decision-making in the weeks ahead.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →